About Luminex Corporation
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company's FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to various types of testing laboratories. The Company's assay products are focused on three segments of the molecular diagnostic testing market: human genetics, personalized medicine and infectious disease.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Instruments & Supplies
- Sub-Industry: Life Sciences Tools & Services
- Exchange: NASDAQ
- Symbol: LMNX
- CUSIP: 55027E10
- Previous Close: $18.25
- 50 Day Moving Average: $20.05
- 200 Day Moving Average: $20.98
- 52-Week Range: $42,768,000.00 - $17.57
- Trailing P/E Ratio: 57.03
- Foreward P/E Ratio: 30.93
- P/E Growth: 1.10
- Market Cap: $780.52M
- Outstanding Shares: 42,768,000
- Beta: 0.59
- Net Margins: 5.10%
- Return on Equity: 5.53%
- Return on Assets: 5.04%
Companies Related to Luminex Corporation:
- Current Ratio: 4.32%
- Quick Ratio: 3.31%
What is Luminex Corporation's stock symbol?
Luminex Corporation trades on the NASDAQ under the ticker symbol "LMNX."
Where is Luminex Corporation's stock going? Where will Luminex Corporation's stock price be in 2017?
7 brokerages have issued 1 year price targets for Luminex Corporation's shares. Their predictions range from $18.00 to $27.00. On average, they anticipate Luminex Corporation's share price to reach $21.33 in the next year.
When will Luminex Corporation announce their earnings?
Luminex Corporation is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.
What are analysts saying about Luminex Corporation stock?
Here are some recent quotes from research analysts about Luminex Corporation stock:
- Piper Jaffray Companies analysts commented, "Luminex announced 4Q16 revenue of $72.3M, in line with preliminary results. Adj. EPS of $0.06 missed the Street's $0.13 estimate. Results in the quarter reflect strong consumables growth, somewhat offset by lighter instrument sales. Management reaffirmed FY17 revenue guidance of $295M-$305M and provided 1Q17 revenue guidance in line with the Street ($73M-$75M; Street: $74.2M). Revenue guidance appears achievable, but we believe shares are fairly valued. We remain Neutral with a $19 price target (was $20) based on ~2.1x FY18 EV/Rev (unchanged) on our revised estimates." (2/7/2017)
According to Zacks Investment Research, "In the past six months, Luminex’s share price over performed the broader industry trend. However, in the last 30 days, earnings estimates have been moved downwards reflecting sluggish third quarter performance. We note that, Luminex reported dismal third quarter 2016 results, missing the Zacks Consensus Estimates on both lines. However, the company raised its revenue guidance for the full-year of 2016. We believe that Luminex's Assay business will be its key growth driver over the long term. We are also optimistic with regard to the company’s products – ARIES and NxTAG RPP, which represent a major revenue opportunity for Luminex. These products will considerably expand the company’s addressable market in the long run. Moreover, the recently completed Nanosphere acquisition expands Luminex's product portfolio. We are also bullish on the company’s promising financial position, which is with no debt, at the end of the" (11/29/2016)
Who owns Luminex Corporation stock?
Luminex Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (3.87%), Renaissance Technologies LLC (3.15%), State Street Corp (2.05%), Fred Alger Management Inc. (1.40%), GSA Capital Partners LLP (0.52%) and Wall Street Access Asset Management LLC (0.51%). Company insiders that own Luminex Corporation stock include G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir and Russell W Bradley.
Who sold Luminex Corporation stock? Who is selling Luminex Corporation stock?
Luminex Corporation's stock was sold by a variety of institutional investors in the last quarter, including Systematic Financial Management LP, Fred Alger Management Inc., Oxford Asset Management, Wall Street Access Asset Management LLC, Raymond James Financial Services Advisors Inc., AQR Capital Management LLC, GSA Capital Partners LLP and O Shaughnessy Asset Management LLC. Company insiders that have sold Luminex Corporation stock in the last year include G Walter Loewenbaum II and Kevin M Mcnamara.
Who bought Luminex Corporation stock? Who is buying Luminex Corporation stock?
Luminex Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Russell Investments Group Ltd., State Street Corp, Congress Asset Management Co. MA, Guggenheim Capital LLC, Martingale Asset Management L P, Trexquant Investment LP and Renaissance Technologies LLC. Company insiders that have bought Luminex Corporation stock in the last two years include G Walter Loewenbaum II, Harriss T Currie and Nachum Shamir.
How do I buy Luminex Corporation stock?
Shares of Luminex Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Luminex Corporation stock cost?
One share of Luminex Corporation stock can currently be purchased for approximately $18.25.